Pascal pushes AZ to push Brilinta in diabetes
This article was originally published in Scrip
Executive Summary
AstraZeneca's re-announcement on 5 December that it will open two new large trials of its commercially less-than-brilliant antiplatelet drug Brilinta (ticagrelor) is further evidence that the company is responding to stinging public criticism from its still untarnished CEO Pascal Soriot. In the company's latest attempt to put the drug back on commercial track, Brilinta (Brilique or Possia outside the US) will be tested in two sets of high cardiovascular risk patients representing hundreds of millions of patients worldwide – type 2 diabetics, on the one hand, and those who have suffered non-fatal ischemic disease on the other. In the diabetes trial, the fact that ticagrelor will go head-to-head with aspirin suggests that AstraZeneca may be willing to be aggressive in combatting the aspirin contraindication that Brilinta/Brilique currently carries.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.